Glaxosmithkline Pharmaceuticals Ltd (GLAXO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 793005,
    "name": "Glaxosmi. Pharma",
    "stock_name": "Glaxosmi. Pharma",
    "full_name": "Glaxosmithkline Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/glaxosmi-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,579.60",
    "chg": 13.05,
    "chgp": "0.51%",
    "dir": 1,
    "prev_price": "2,566.55",
    "mcapval": "43,404.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 500660,
    "symbol": "GLAXO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE159A01016",
    "curr_date": "Aug 06, 03:30 PM",
    "curr_time": "08:39 AM",
    "last_traded_at": "Aug 06, 03:30 PM IST",
    "bse_nse_vol": "41.65 k",
    "exc_status": "Active",
    "traded_date": "Aug 06, 2026",
    "traded_date_str": "2026 08 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Mixed Technical Signals Amid Price Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-mixed-technical-signals-amid-price-momentum-shift-4139160",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/Glaxosmithkline_technicaldot_4139160.png",
        "date": "2026-08-06 08:03:54",
        "description": "Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in price momentum, transitioning from a sideways trend to a mildly bearish stance. Despite some bullish weekly technical indicators, the overall monthly outlook remains cautious, reflecting a complex interplay of market forces and investor sentiment within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-glaxosmithkline-pharmaceuticals-ltd-latest-results-good-or-bad-4136156",
        "imagepath": "",
        "date": "2026-08-04 19:20:50",
        "description": "GlaxoSmithKline Pharmaceuticals Ltd's latest financial results for Q1 FY27 present a complex picture of operational performance. The company reported net sales of ₹938.44 crores, reflecting a year-on-year growth of 16.55%. However, there was a sequential decline of 5.71% from the previous quarter, indicating potential challenges in sustaining demand. \n\nNet profit for the quarter was ₹237.18 crores, which is a 15.69% increase year-on-year but shows a significant 14.64% decrease compared to the previous quarter. This decline raises concerns about the company's profitability trajectory, particularly as the profit after tax margin fell to 25.27%, down from 27.92% in the prior quarter.\n\nOperating margins also contracted, decreasing to 31.49% from 35.26% in the previous quarter, which signals mounting cost pressures. The company is facing challenges with rising employee costs and other operational expenditures, c..."
      },
      {
        "title": "GlaxoSmithKline Pharmaceuticals Q1 FY27: Profit Growth Masks Margin Compression Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/glaxosmithkline-pharmaceuticals-q1-fy27-profit-growth-masks-margin-compression-concerns-4134183",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/Glaxosmithkline_quaterlyResult_4134183.png",
        "date": "2026-08-03 21:16:26",
        "description": "GlaxoSmithKline Pharmaceuticals Ltd. reported a 15.69% year-on-year increase in net profit to ₹237.18 crores for Q1 FY27 ended June 2026, though sequential momentum faltered with a 14.64% quarter-on-quarter decline. The mid-cap pharmaceutical company, valued at ₹44,793 crores, delivered mixed signals as revenue growth of 16.55% YoY to ₹938.44 crores was overshadowed by margin compression and sequential profit deterioration."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-4132931",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/Glaxosmithkline_technicaldot_4132931.png",
        "date": "2026-08-03 08:02:25",
        "description": "Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent upgrade in daily price action, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of this mid-cap pharmaceutical player, contextualising its price movements against broader market benchmarks and sectoral trends."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-signals-4127896",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/Glaxosmithkline_technicaldot_4127896.png",
        "date": "2026-07-30 08:02:01",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s recent performance and underlying metrics suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-signals-4125107",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/Glaxosmithkline_technicaldot_4125107.png",
        "date": "2026-07-29 08:02:48",
        "description": "Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a strong day change of 3.57%, the stock’s technical indicators reveal a transition from a mildly bearish trend to a sideways momentum, prompting a reassessment of its near-term outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-4124225",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/Glaxosmithkline_mojoScore_4124225.png",
        "date": "2026-07-28 10:10:03",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-4106335",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/Glaxosmithkline_mojoScore_4106335.png",
        "date": "2026-07-17 10:10:04",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are current as of 17 July 2026, providing investors with an up-to-date view of the company’s performance and valuation."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-4090728",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/Glaxosmithkline_mojoScore_4090728.png",
        "date": "2026-07-06 10:10:05",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      }
    ],
    "total": 5207,
    "sid": "793005",
    "stock_news_url": "https://www.marketsmojo.com/news/glaxosmithkline-pharmaceuticals-793005"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "04-Aug-2026",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "03-Aug-2026",
      "details": "Reappointment of Managing Director",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "03-Aug-2026",
      "details": "As per attachment",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>570%</strong> dividend, ex-date: 29 May 26",
          "dt": "2026-05-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
          "dt": "2018-09-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glaxosmithkline Pharmaceuticals Ltd Faces Mixed Technical Signals Amid Price Momentum Shift

2026-08-06 08:03:54

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in price momentum, transitioning from a sideways trend to a mildly bearish stance. Despite some bullish weekly technical indicators, the overall monthly outlook remains cautious, reflecting a complex interplay of market forces and investor sentiment within the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?

2026-08-04 19:20:50

GlaxoSmithKline Pharmaceuticals Ltd's latest financial results for Q1 FY27 present a complex picture of operational performance. The company reported net sales of ₹938.44 crores, reflecting a year-on-year growth of 16.55%. However, there was a sequential decline of 5.71% from the previous quarter, indicating potential challenges in sustaining demand. Net profit for the quarter was ₹237.18 crores, which is a 15.69% increase year-on-year but shows a significant 14.64% decrease compared to the previous quarter. This decline raises concerns about the company's profitability trajectory, particularly as the profit after tax margin fell to 25.27%, down from 27.92% in the prior quarter. Operating margins also contracted, decreasing to 31.49% from 35.26% in the previous quarter, which signals mounting cost pressures. The company is facing challenges with rising employee costs and other operational expenditures, c...

Read full news article

GlaxoSmithKline Pharmaceuticals Q1 FY27: Profit Growth Masks Margin Compression Concerns

2026-08-03 21:16:26

GlaxoSmithKline Pharmaceuticals Ltd. reported a 15.69% year-on-year increase in net profit to ₹237.18 crores for Q1 FY27 ended June 2026, though sequential momentum faltered with a 14.64% quarter-on-quarter decline. The mid-cap pharmaceutical company, valued at ₹44,793 crores, delivered mixed signals as revenue growth of 16.55% YoY to ₹938.44 crores was overshadowed by margin compression and sequential profit deterioration.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-08-03 08:02:25

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent upgrade in daily price action, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of this mid-cap pharmaceutical player, contextualising its price movements against broader market benchmarks and sectoral trends.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals

2026-07-30 08:02:01

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s recent performance and underlying metrics suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals

2026-07-29 08:02:48

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a strong day change of 3.57%, the stock’s technical indicators reveal a transition from a mildly bearish trend to a sideways momentum, prompting a reassessment of its near-term outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-07-28 10:10:03

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-07-17 10:10:04

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are current as of 17 July 2026, providing investors with an up-to-date view of the company’s performance and valuation.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-07-06 10:10:05

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

View All News